Ben Conway

Ben Conway

Managing Director

Mr. Conway has over 20 years experience in life science investment banking with transaction experience involving mergers & acquisitions, public and private equity financings and strategic partnerships across an array of life science sectors including biotechnology, specialty pharmaceuticals, medical device, diagnostics and the ancillary services sectors.  Prior to joining Consilium, he was managing director of Johnston Blakely & Company, a boutique life science investment bank he founded in 2002 and subsequently acquired by CMC Consulting. Previously, Mr. Conway was group head of biotechnology investment banking at Adams, Harkness & Hill, a Boston-based investment bank where he led the Adams, Harkness group to a top ranking for completed middle market M&A transactions.  Mr. Conway’s experience also includes positions with Abbott Laboratories and Bain & Company.

Representative life science transactions include the acquisition by Anika Therapeutics (NASDAQ: ANIK) of Fidia Advanced Biopolymers s.r.l., the growth equity investment in CutisPharma by Ampersand Capital Partners, the acquisition of the NGS supply-chain services business of ArcherDx by TCP Reliable and the acquisition of Vitality Pharmaceutical Services by Bioscrip (NASDAQ: BIOS).  The aggregate value of completed transactions exceeds $1 billion.

Mr. Conway received an M.B.A., with honors, from the Harvard Business School and an A.B., magna cum laude, from Bowdoin College, and holds FINRA Series 7, 63, 79 and 24 licenses.